{
    "clinical_study": {
        "@rank": "72212", 
        "arm_group": {
            "arm_group_label": "preoperative concurrent chemoradiation", 
            "arm_group_type": "Experimental", 
            "description": "Radiation is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation."
        }, 
        "brief_summary": {
            "textblock": "The aim of this study is to find some genetic factors in predicting the sensibility of\n      preoperative chemoradiotherapy for locally advanced rectal carcinoma."
        }, 
        "brief_title": "Genetic Profile on Predicting Sensibility of Preoperative Chemoradiotherapy on Locally Advanced Rectal Carcinoma", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Rectal Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Carcinoma", 
                "Rectal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "For locally advanced rectal carcinoma,preoperative chemoradiotherapy(CRT) achieved similar\n      overall survival and better local control compared with postoperative therapy,so it was\n      considered to be one of the standard therapy of these patients.But,not every one will be\n      cured,the possible reason is the difference gene expression and mutation status among\n      patients.So,we performed this trial to study the relationship between genetic factors and\n      response of preoperative CRT for locally advanced rectal cancer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pathologically confirmed rectal adenocarcinoma, preoperative stage II / III (T3-4N0\n             or T1-4N + M0).\n\n          -  Distance from the lower bound of tumor to the anal verge is less than 12 cm.\n\n          -  KPS score not less than 70\n\n          -  Can be tolerated chemotherapy and radiotherapy.\n\n          -  No history of radiation therapy to the pelvis.\n\n          -  Non-allergic history of fluorouracil or platinum-based chemotherapy drugs.\n\n          -  Full understanding of the study, the ability to complete all of the treatment plan,\n             follow up the conditions and sign the informed consent.  -\n\n        Exclusion Criteria:\n\n          -  Other malignancy (past or at the same time), does not include curable non-melanoma\n             skin cancer and cervical carcinoma in situ; does not include resectable primary colon\n             cancer (synchronous or metachronous).\n\n          -  Pregnant or lactating patients.\n\n          -  Fertility but did not use contraceptive measures.\n\n          -  Existing active infection.\n\n          -  Merge serious complications, can not tolerate the treatment, such as 6 months of\n             myocardial infarction, mental illness, uncontrollable diabetes or uncontrollable\n             hypertension or hypotension.\n\n          -  Concurrent treatment with other anticancer drugs.\n\n          -  Can not complete treatment or follow-up"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01930942", 
            "org_study_id": "D0905001040531"
        }, 
        "intervention": {
            "arm_group_label": "preoperative concurrent chemoradiation", 
            "description": "Radiation is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.", 
            "intervention_name": "preoperative concurrent chemoradiation", 
            "intervention_type": "Radiation"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "rectal carcinoma", 
            "preoperative concurrent chemoradiotherapy"
        ], 
        "lastchanged_date": "August 26, 2013", 
        "location": {
            "contact": {
                "email": "jingjin1025@163.com", 
                "last_name": "Jing Jin, MD", 
                "phone": "+8613601365130"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100021"
                }, 
                "name": "Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Genetic Profile on Predicting Sensibility of Preoperative Chemoradiotherapy on Locally Advanced Rectal Carcinoma", 
        "other_outcome": {
            "description": "any G3/4 toxicities according to CTC 3.0", 
            "measure": "toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "during concurrent chemoradiation"
        }, 
        "overall_contact": {
            "email": "jingjin1025@163.com", 
            "last_name": "Jing Jin, MD", 
            "phone": "+86-13601365130"
        }, 
        "overall_official": {
            "affiliation": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College", 
            "last_name": "Jing Jin, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Science and Technology", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "gene expression in different response groups", 
            "safety_issue": "No", 
            "time_frame": "6 months after radical surgery"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01930942"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese Academy of Medical Sciences", 
            "investigator_full_name": "Jing Jin, M.D.", 
            "investigator_title": "Vice Director of Abdomen Division, Radiation Oncology Department", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "overall survival, disease free survival and local-regional free survival", 
            "safety_issue": "No", 
            "time_frame": "3 years after pre-operative chemoradiotherapy"
        }, 
        "source": "Chinese Academy of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chinese Academy of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2006", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}